Exhibit 99.1

 

AGREEMENT OF THE REPORTING PERSONS

 

The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the other, except to the extent that such person or entity knows or has reason to believe that such information is inaccurate. This agreement may be executed in any number of counterparts and all of such counterparts taken together shall constitute one and the same instrument. 

 

Date: March 24, 2025
 
BLEICHROEDER LP
Signature: /s/ Andrew Gundlach
Name/Title: Andrew Gundlach, Chairman and CEO
 
BLEICHROEDER HOLDINGS LLC
Signature: /s/ Andrew Gundlach
Name/Title: Andrew Gundlach, Chairman and CEO
 
ANDREW GUNDLACH
Signature: /s/ Andrew Gundlach
Name/Title: Andrew Gundlach, Individual

Exhibit 99.2

The identity and the Item 3 classification of the relevant subsidiary is: Bleichroeder LP, which is an Investment Adviser in accordance with Rule 13d-1(b)(1)(ii)(E).

Grafico Azioni Aptose Biosciences (NASDAQ:APTO)
Storico
Da Mar 2025 a Apr 2025 Clicca qui per i Grafici di Aptose Biosciences
Grafico Azioni Aptose Biosciences (NASDAQ:APTO)
Storico
Da Apr 2024 a Apr 2025 Clicca qui per i Grafici di Aptose Biosciences